Minke He
About
Minke He is a scholar working on Pathology and Forensic Medicine, Hepatology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Minke He has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 16 papers in Hepatology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Minke He's work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer Mechanisms and Therapy (15 papers) and Renal cell carcinoma treatment (8 papers). Minke He is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer Mechanisms and Therapy (15 papers) and Renal cell carcinoma treatment (8 papers). Minke He collaborates with scholars based in China, Hong Kong and United States. Minke He's co-authors include Ming Shi, QiJiong Li, Yong Le, Li Xu, Rong Guo, Wei Wei, ZhiCheng Lai, MinShan Chen, Zhongguo Zhou and JingXian Shen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Frontiers in Immunology.
In The Last Decade
Minke He
37 papers receiving 1.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Minke He China | 14 | 799 | 412 | 313 | 234 | 234 | 41 | 1.1k | ||
| QiJiong Li China | 18 | 919 1.2× | 463 1.1× | 382 1.2× | 242 1.0× | 297 1.3× | 33 | 1.3k | ||
| Hirokazu Chishina Japan | 18 | 900 1.1× | 275 0.7× | 199 0.6× | 195 0.8× | 225 1.0× | 44 | 1.1k | ||
| Florian Hucke Austria | 13 | 1.0k 1.3× | 286 0.7× | 281 0.9× | 197 0.8× | 235 1.0× | 28 | 1.3k | ||
| Fabrício Henrique Pereira De Souza United States | 6 | 648 0.8× | 195 0.5× | 225 0.7× | 112 0.5× | 218 0.9× | 8 | 950 | ||
| Wen‐Feng Gong China | 14 | 800 1.0× | 140 0.3× | 277 0.9× | 156 0.7× | 324 1.4× | 29 | 1.1k | ||
| Yong Le China | 10 | 464 0.6× | 216 0.5× | 189 0.6× | 129 0.6× | 131 0.6× | 11 | 652 | ||
| A. Baldan Italy | 7 | 647 0.8× | 167 0.4× | 162 0.5× | 121 0.5× | 137 0.6× | 10 | 862 | ||
| Kerry Horgan United States | 9 | 470 0.6× | 276 0.7× | 250 0.8× | 246 1.1× | 353 1.5× | 13 | 962 | ||
| Miho Kanda Japan | 9 | 567 0.7× | 127 0.3× | 282 0.9× | 172 0.7× | 187 0.8× | 15 | 759 | ||
| Bolorsukh Gansukh United States | 6 | 421 0.5× | 164 0.4× | 156 0.5× | 141 0.6× | 261 1.1× | 8 | 847 |
Countries citing papers authored by Minke He
Since
Specialization
Citations
This map shows the geographic impact of Minke He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minke He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minke He more than expected).
Fields of papers citing papers by Minke He
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Minke He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minke He. The network helps show where Minke He may publish in the future.
Co-authorship network of co-authors of Minke He
This figure shows the co-authorship network connecting the top 25 collaborators of Minke He. A scholar is included among the top collaborators of Minke He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minke He. Minke He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kan, Anna, Minke He, Huifang Li, et al.. (2024). Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Frontiers in Immunology. 15. 1260191–1260191.
2.
Lai, ZhiCheng, et al.. (2024). Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).. Journal of Clinical Oncology. 42(16_suppl). 4113–4113.
3.
Huang, Jiaqi, He Chang, Peirong Xu, et al.. (2024). Development and validation of a clinical-radiomics model for prediction of prostate cancer: a multicenter study. World Journal of Urology. 42(1). 275–275.
4.
Lai, ZhiCheng, Anna Kan, Hui Liu, et al.. (2024). TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma. Frontiers in Bioscience-Landmark. 29(7). 243–243.
5.
He, Minke, ZhiCheng Lai, QiJiong Li, et al.. (2023). Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Current Opinion in Pharmacology. 70. 102362–102362.
6.
Kan, Anna, Shuang Liu, Minke He, et al.. (2023). MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma. JHEP Reports. 6(1). 100939–100939.
7.
Zhang, Huawei, et al.. (2023). The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth via the PI3K/AKT Signaling Pathway. Combinatorial Chemistry & High Throughput Screening. 27(13). 1984–1998.
8.
Huang, Jiaqi, Yaohui Li, Minke He, et al.. (2022). Prognostic evaluation based on radiological morphological characteristic for tumors larger than 7 cm in renal cell carcinoma. Journal of Cancer Research and Clinical Oncology. 149(1). 263–270.
9.
Lai, ZhiCheng, Minke He, Yu-Jie Xu, et al.. (2022). Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer. 174. 68–77.
10.
He, Chang, Fan Yang, Zhuifeng Guo, et al.. (2021). Denonvilliers’ fascia acts as the fulcrum and hammock for continence after radical prostatectomy. BMC Urology. 21(1). 176–176.
11.
Xu, Yu-Jie, et al.. (2021). Construction of a single nucleotide variant score-related gene-based prognostic model in hepatocellular carcinoma: analysis of multi-independent databases and validation in vitro. Cancer Cell International. 21(1). 610–610.
12.
He, Minke, Chuan Peng, Yang Zhao, et al.. (2021). Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunology Immunotherapy. 70(11). 3207–3216.
13.
Zhao, Yang, Minke He, Dongsheng Wen, et al.. (2021). Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Frontiers in Oncology. 11. 619461–619461.
14.
Le, Yong, Anna Kan, QiJiong Li, et al.. (2019). NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma. Cancer Cell International. 19(1). 228–228.
15.
Zhao, Yang, et al.. (2019). Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma. SHILAP Revista de lepidopterología. 2(2). 78–83.
16.
Le, Yong, Jingxian Shen, Yongfa Zhang, et al.. (2019). Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. Journal of Cancer. 10(3). 665–671.
17.
Le, Yong, Peng Jiang, Hui Tang, et al.. (2018). Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy. Cancer Medicine. 7(11). 5339–5350.
18.
He, Minke, Ruhai Zou, QiJiong Li, et al.. (2018). Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. CardioVascular and Interventional Radiology. 41(5). 734–743.
19.
He, Minke, et al.. (2018). Short interval of biopsy to robotic-assisted laparoscopic radical prostatectomy does not render any adverse effects on the perioperative outcomes. Medicine. 97(36). e11686–e11686.
20.
He, Minke, Yong Le, QiJiong Li, et al.. (2017). Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chinese Journal of Cancer. 36(1). 83–83.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by QiJiong Li Breakdown of academic impact, for papers by Hirokazu Chishina Breakdown of academic impact, for papers by Florian Hucke Breakdown of academic impact, for papers by Fabrício Henrique Pereira De Souza Breakdown of academic impact, for papers by Wen‐Feng Gong Breakdown of academic impact, for papers by Yong Le Breakdown of academic impact, for papers by A. Baldan Breakdown of academic impact, for papers by Kerry Horgan Breakdown of academic impact, for papers by Miho Kanda Breakdown of academic impact, for papers by Bolorsukh Gansukh